Suggested Remit: To appraise the clinical and cost effectiveness of avapritinib within its marketing authorisation for unresectable or metastatic gastrointestinal stromal tumours (GIST).
Status In progress
Process STA 2018
ID number 1626

Provisional Schedule

Expected publication 16 December 2020

Project Team

Project lead Emily Richards

Email enquiries


Key events during the development of the guidance:

Date Update
09 September 2019 As you will be aware, the Department for Health and Social Care has asked NICE to conduct an appraisal of avapritinib for treating unresectable or metastatic gastrointestinal stromal tumours. Please note that following on from advice received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in early-February 2020. These timings are based on a request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive and robust evidence submission.
31 July 2019 - 29 August 2019 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
29 April 2019 In progress, DHSC Referral Received

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance